Pulse nav.journalClub Debates activos Tendencias Explorar Investigadores

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

Semaglutide Eligibility Across All Current Indications for US Adults | Synapse

November 18, 2024Open Access

Semaglutide Eligibility Across All Current Indications for US Adults

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

This cross-sectional study uses National Health and Nutrition Examination Survey data to examine the number of US adults eligible for semaglutide across all current indications.

Leer artículo completoexternamente

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Shi et al. (Mon,) studied this question.

synapsesocial.com/papers/69863856db3aef8684169edd https://doi.org/https://doi.org/10.1001/jamacardio.2024.4657

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity2021 · 1,020 citations
2Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes2023 · 2,686 citations
3Poll: Roughly 12% of US Adults Have Used a GLP-1 Drug, Even If Unaffordable2024 · 42 citations
4Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trials2019 · 283 citations
5Projected Changes in Statin and Antihypertensive Therapy Eligibility With the AHA PREVENT Cardiovascular Risk Equations2024 · 88 citations